EO4010 in Previously Treated Metastatic Colorectal Carcinoma
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Enterome
- Target Recruit Count
- 42
- Registration Number
- NCT05589597
- Locations
- 🇪🇸
Llavero-Hospital Clínico Universitario, Valencia, Spain
🇺🇸MD Anderson, Houston, Texas, United States
🇫🇷Hôpital Jean Minjoz, Besançon, France
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Enterome
- Target Recruit Count
- 1
- Registration Number
- NCT05350501
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Enterome
- Target Recruit Count
- 60
- Registration Number
- NCT04669171
- Locations
- 🇫🇷
CHU d'Amiens-Picardie - Hopital SUD, Amiens, France
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
- Conditions
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Enterome
- Target Recruit Count
- 70
- Registration Number
- NCT04187404
- Locations
- 🇫🇷
Chu Lille, Lille, France
🇫🇷Assistance Publique - Hôpitaux de Marseille - Hôpital Nord, Marseille, France
🇫🇷Institut Gustave Roussy, Villejuif, France
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Enterome
- Target Recruit Count
- 100
- Registration Number
- NCT04116658
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇪🇸Institit Catala D'Oncologia - Hospital Duran i Reynals, Hospitalet De Llobregat, Spain
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Enterome
- Target Recruit Count
- 8
- Registration Number
- NCT03709628
- Locations
- 🇦🇹
Medical University Vienna, Wien, Austria
🇫🇷Hôpital Claude Huriez, Lille, France
🇩🇪Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany
First-in-Human Single and Multiple Dose of EB8018
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Enterome
- Target Recruit Count
- 60
- Registration Number
- NCT02998190
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Enterome
- Target Recruit Count
- 143
- Registration Number
- NCT02882841
- Locations
- 🇫🇷
Hôpital Saint-Antoine, Paris, France
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
🇬🇧Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom